Skip to main content
Top
Published in: Medical Oncology 9/2014

01-09-2014 | Original Paper

Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival

Authors: Wenfeng Li, Zhengyang Xu, Junfeng Hong, Yunsheng Xu

Published in: Medical Oncology | Issue 9/2014

Login to get access

Abstract

Enhanced glycolysis is a common trait of many types of human cancers. This study was to detect the expression pattern of three regulatory enzymes during glycolysis in esophageal squamous cell carcinoma (ESCC) and to investigate their correlation with patients’ outcome based on banked pathology material. A total of 141 surgically resected specimens of primary ESCC patients without prior treatments were retrospectively recruited from the First Affiliated Hospital of Wenzhou Medical College Hospital from 2007 to 2009. Expression of HK1, PFKB, and PKM2 in ESCC specimens was analyzed by immunohistochemical staining and Western blotting analysis. HK1-shRNA was used to knock down HK1 expression in ESCC cells, and the functional significance was assessed by CCK8 assay. It was found that the expression of two glycolytic enzymes, HK1 and PKM2, was associated with disease progression, invasion, and poor survival of patients with ESCC. Silence of HK1-inhibited cell proliferation in vitro and suppressed phospho-S6 kinase expression. Our findings suggest that activation of key enzymes in glycolysis might serve as potential therapeutic targets and/or prognostic factors for patients with ESCC.
Literature
1.
go back to reference Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.PubMedCrossRef Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.PubMedCrossRef
2.
go back to reference Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB, Hochwald SN. Esophageal cancer—the five year survivors. J Surg Oncol. 2011;103(2):179–83.PubMedCrossRef Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB, Hochwald SN. Esophageal cancer—the five year survivors. J Surg Oncol. 2011;103(2):179–83.PubMedCrossRef
3.
go back to reference Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. Esophageal cancer: an update. Int J Surg. 2010;8(6):417–22.PubMedCrossRef Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. Esophageal cancer: an update. Int J Surg. 2010;8(6):417–22.PubMedCrossRef
4.
5.
go back to reference Yokobori T, Kuwano H. Molecular biological review of esophageal cancer. Kyobu geka Japanese J Thorac Surg. 2013;66(1):73–84. Yokobori T, Kuwano H. Molecular biological review of esophageal cancer. Kyobu geka Japanese J Thorac Surg. 2013;66(1):73–84.
6.
go back to reference Lepage C, Drouillard A, Jouve JL, Faivre J. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis. 2013;45(8):625–9.PubMedCrossRef Lepage C, Drouillard A, Jouve JL, Faivre J. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis. 2013;45(8):625–9.PubMedCrossRef
7.
go back to reference Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta. 2012;1825(1):111–6.PubMed Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta. 2012;1825(1):111–6.PubMed
9.
go back to reference Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study. PLoS Genet. 2008;4(12):e1000312.PubMedCrossRefPubMedCentral Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study. PLoS Genet. 2008;4(12):e1000312.PubMedCrossRefPubMedCentral
10.
go back to reference Bonnefond A, Vaxillaire M, Labrune Y, Lecoeur C, Chevre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, et al. Genetic variant in HK1 is associated with a proanemic state and A1C but not other glycemic control-related traits. Diabetes. 2009;58(11):2687–97.PubMedCrossRefPubMedCentral Bonnefond A, Vaxillaire M, Labrune Y, Lecoeur C, Chevre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, et al. Genetic variant in HK1 is associated with a proanemic state and A1C but not other glycemic control-related traits. Diabetes. 2009;58(11):2687–97.PubMedCrossRefPubMedCentral
11.
go back to reference Pinney SE, Ganapathy K, Bradfield J, Stokes D, Sasson A, Mackiewicz K, Boodhansingh K, Hughes N, Becker S, Givler S, et al. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Horm Res Paediatr. 2013;80(1):18–27.PubMed Pinney SE, Ganapathy K, Bradfield J, Stokes D, Sasson A, Mackiewicz K, Boodhansingh K, Hughes N, Becker S, Givler S, et al. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Horm Res Paediatr. 2013;80(1):18–27.PubMed
12.
go back to reference Jiang L, Ren J, Xiao X, Tang YY, Weng HQ, Yang Q, Wu MJ, Tang W. Proteomic analysis of bladder cancer by iTRAQ after bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment. Biol Chem. 2013;394(10):1333–42.PubMedCrossRef Jiang L, Ren J, Xiao X, Tang YY, Weng HQ, Yang Q, Wu MJ, Tang W. Proteomic analysis of bladder cancer by iTRAQ after bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment. Biol Chem. 2013;394(10):1333–42.PubMedCrossRef
13.
go back to reference Filipp FV. Cancer metabolism meets systems biology: pyruvate kinase isoform PKM2 is a metabolic master regulator. J Carcinogenesis. 2013;12:14.CrossRef Filipp FV. Cancer metabolism meets systems biology: pyruvate kinase isoform PKM2 is a metabolic master regulator. J Carcinogenesis. 2013;12:14.CrossRef
15.
go back to reference Zhang X, He C, He C, Chen B, Liu Y, Kong M, Wang C, Lin L, Dong Y, Sheng H. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract. 2013;209(8):510–5.PubMedCrossRef Zhang X, He C, He C, Chen B, Liu Y, Kong M, Wang C, Lin L, Dong Y, Sheng H. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract. 2013;209(8):510–5.PubMedCrossRef
16.
go back to reference Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans. 2013;41(4):917–22.PubMedCrossRef Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans. 2013;41(4):917–22.PubMedCrossRef
17.
go back to reference Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, Jiang Y, Zhou X, Li TT, Guan KL, et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell. 2013;52(3):340–52.PubMedCrossRefPubMedCentral Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, Jiang Y, Zhou X, Li TT, Guan KL, et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell. 2013;52(3):340–52.PubMedCrossRefPubMedCentral
18.
go back to reference Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y et al: PKM2 Regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell. 2014;53(1):75–87. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y et al: PKM2 Regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell. 2014;53(1):75–87.
19.
go back to reference Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892–9.PubMedCrossRef Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892–9.PubMedCrossRef
20.
go back to reference Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39(7–8):1358–66.PubMedCrossRef Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39(7–8):1358–66.PubMedCrossRef
21.
go back to reference Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, Kim YB, Song YS. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 2013. doi:10.1007/s10238-013-0250-9. Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, Kim YB, Song YS. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 2013. doi:10.​1007/​s10238-013-0250-9.
22.
go back to reference Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D’Alessandro A, Zolla L, Finazzi Agro A, et al. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013;32(6):797–802.PubMedCrossRef Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D’Alessandro A, Zolla L, Finazzi Agro A, et al. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013;32(6):797–802.PubMedCrossRef
23.
go back to reference Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer. 2012;12:232.PubMedCrossRef Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer. 2012;12:232.PubMedCrossRef
24.
go back to reference Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H. Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2009;56(90):355–60.PubMed Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H. Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2009;56(90):355–60.PubMed
25.
go back to reference Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res MCR. 2009;7(9):1438–45.CrossRef Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res MCR. 2009;7(9):1438–45.CrossRef
26.
go back to reference Peng QP, Zhou JM, Zhou Q, Pan F, Zhong DP, Liang HJ. Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy. 2008;54(5):357–63.PubMedCrossRef Peng QP, Zhou JM, Zhou Q, Pan F, Zhong DP, Liang HJ. Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy. 2008;54(5):357–63.PubMedCrossRef
27.
go back to reference Gjesing AP, Nielsen AA, Brandslund I, Christensen C, Sandbaek A, Jorgensen T, Witte D, Bonnefond A, Froguel P, Hansen T, et al. Studies of a genetic variant in HK1 in relation to quantitative metabolic traits and to the prevalence of type 2 diabetes. BMC Med Genet. 2011;12:99.PubMedCrossRefPubMedCentral Gjesing AP, Nielsen AA, Brandslund I, Christensen C, Sandbaek A, Jorgensen T, Witte D, Bonnefond A, Froguel P, Hansen T, et al. Studies of a genetic variant in HK1 in relation to quantitative metabolic traits and to the prevalence of type 2 diabetes. BMC Med Genet. 2011;12:99.PubMedCrossRefPubMedCentral
Metadata
Title
Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival
Authors
Wenfeng Li
Zhengyang Xu
Junfeng Hong
Yunsheng Xu
Publication date
01-09-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 9/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0118-1

Other articles of this Issue 9/2014

Medical Oncology 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.